Home › Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC
 

Keywords :   


Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

2015-02-14 13:04:00| Biotech - Topix.net

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer . LENVIMA was approved following a priority review by the FDA, which is designated for drugs the FDA believes have the potential to provide a significant improvement in the treatment of a serious condition.

Tags: treatment approval announces fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.09Cathay Airbus fault could have caused major damage
19.09PPG Celebrates Success of WorldSkills Lyon 2024 Vocational Skills Event
19.09Asahi Kasei Launches New Grade of Flame Retardant Nonwoven
19.09KT Capital Acquires Majority Interest in Recycling Equipment Incorporated
19.09One in five passengers forced to stand in morning peak
19.09LRS Exchange MRF Wins 2024 NWRA Recycling Facility of the Year Award
19.09Researchers find potential for Babraham pig to be used as a biomedical model
19.09Bristol Motor Speedway, Keep Tennessee Beautiful Partner on Cigarette Litter Prevention and Recycling
More »